You are here

THE EVALUATION OF SELENIUM AND THYROID HORMONES AMONG THE POPULATION WITH DIABETES MELLITUS

THE EVALUATION OF SELENIUM AND THYROID HORMONES AMONG THE POPULATION WITH DIABETES MELLITUS

Journal Name:

Publication Year:

Abstract (2. Language): 
Background: The aim of this study is to evaluate the association between selenium and thyroid hormones among diabetes. Both diabetes and thyroid disorders involves dysfunction of the endocrine system. Materials & Methods: both type I & II diabetes mellitus patients attending the Diabetic OP of Melmaruvathur Adhiparasakthi Institute of Medical Sciences and Research, Melmaruvathur, Tamilnadu. Study was conducted on 46 diabetes(30 NIDDM & 16 IDDM) along with 30 age sex matched healthy control in age group between 45-75years. The investigations carried out were FBS, HbA1c, Thyroid Profile and Selenium. Results:- In both Type I & II diabetes There were increased FBS, Hb A1c levels , decreased serum selenium &T3 was observed. The higher prevalence of thyroid dysfunction in both type I & II diabetes than in the general population. In type I DM the T3 syndrome is more severe than Type II DM. Conclusion: - Rigorous Selenium & thyroid profile monitoring & control needs to be followed as it is known for health benefits, so as to prevent Diabetic complications & cardiovascular disease, thereby increasing the quality of life among diabetics.
251-258

REFERENCES

References: 

1. Solomons N. Trace Elements. In‘Clinical Nutrition: Parenteral Nutrition’ 2nd edition.
Philadelphia, USA.1993; pp. 150-183.
2. Standbury J.B. and Kroc R.L.Human Development and the Thyroid Gland:Relation to
Endemic Cretinism, PlenumPress, New York.2000; p 19.
3. Tapiero H. and Tew K.D. Trace elements in human physiology and pathology: zinc
and metallothioneins.Biomedicine and Pharmocotherapy 2003;57 (9): 399-411.
4. Stefanidou M., Maravelias C., Dona A., and Spiliopoulou C. Zinc: a
multipurpose trace element. Arch Toxicology,2006; 80 (1): 1-9.
5. Aschner M. Manganese as a potential confounder of serum prolactin. Environ Health
Perspective 2006;114(8):A458.
6. Schomburg L. and Köhrle J.On the importance of selenium and iodine metabolism for thyroid
hormone biosynthesis and human health. Mol Nutrition Food Research 2008;52 (11):
1235- 46.
Indian Journal of Basic & Applied Medical Research; September 2012: Vol.-1, Issue-4, P. 251-258
257
www.ijbamr.com
7. Kvicala J. and Zamrazil V. Effect of iodine and selenium upon thyroid function. Cent-
Eur-J-Public-Health. 2003;11(2): 107-13.
8. Burk RF: Selenium, an antioxidant nutrient. Nutr. Clin. Care.2002; 5:75– 79.
9. Cao YZ, Reddy CC, Sordillo LM: Altered eicosanoid biosynthesis in selenium-deficient
endothelial cells. Free Radic Biol Med.2000; 28: 381–389.
10. Steinberg D: Antioxidants and atherosclerosis. A current assessment. Circulation.1991;
84:1420-1425.
11 . Douillet C, Bost M, Accominotti M, Borson-Chazot F, Ciavatti M: Effect of selenium and
vitamin E supplementation on lipid abnormalities i plasma, aorta, and adipose tissue of
Zucker rats. Trace Elem Res.1998; 65:221–236.
12. Stapleton SR: Selenium: an insulin-mimetic. Cell Mol Life Sci 2000; 57:1874–1879.
13. Levander OA: A global view of human selenium nutrition. Annu Rev Nutr.1987;7:227–250.
14. Robbins J. Factors altering thyroid hormone metabolism. Environ Health Perspect 1981;38:
65-70.
15. Kohrle J, Spanka M, Irmscher K, Hesch RD. Flavonoid effects on transport, metabolism and
action of Visser TJ. Pathways of thyroid hormon metabolism. Acta. Med.
Austriaca,1996;23:10-16.
16. Kohrle J. Thyroid hormone deiodinases--a selenoenzyme family acting as gate keepers to
thyroid Hormone action. Acta Med Austriaca 1996;23:17- 30.
17. Chopra IJ. An assessment of daily production and significance of thyroidal secretion of
3,3',5' triiodithyronine (reverse T3) in man. J Clin Invest.1976:58:32-40.
18. Utiger R. Decreased extrathyroidal triiodothyronine production in non-thyroidal illness:
benefit or harm? Am J Med 1980;69:807-810.
19. St Germain DL, Galton VA. The deiodinase family of selenoproteins. Thyroid 1997;7:655-
668.
20. Beckett GJ, Arthur JR. Hormone-nuclear receptor interactions in health and disease. The
Iodothyronine deiodinases and 5'-deiodination. Baillieres Clin Endocrinol Metab 1994;8:285-
304.
21. Perros P, Mc Crimmon RJ, Shaw G, Frier BM. Frequency of thyroid dysfunction in diabetic
patients: Value of annual screening. Diabet Med 1995; 12 (7): 622-627.
22. Schlienger JL, Anceau A, Chabrier G, North ML, Stephan F. Effect of diabetic control on the
level of circulating thyroid hormones. Diabetologia.1982; 22; 486-8.
23. Donckier JE. Endocrine diseases and diabetes. In: Text book of Diabetes mellitus. Pickup
JC,Williams G (eds), Blackwell Publishing Company, Chichester, 2003: 27.1 – 27.25.
24. Coiro V, Volpi R, Marchesi C, et al. Influence of residual C-peptide secretion on nocturnal
serum TSH peak in well-controlled diabetic patients. Clin.Endocrinol. 1997; 47: 305-10.
25. O’Mara BA, Dittrich W, Lauterio TJ & St Germain DL; Pretranslational regulation of
Indian Journal of Basic & Applied Medical Research; September 2012: Vol.-1, Issue-4, P. 251-258
258
www.ijbamr.com
type I 5 – deiodinase by thyroid hormones and in fasted and diabetic rats. Endocrinology
1993;133: 1715–1723.
26. Polikar R, Burger AG, Scherrer U, et al. The thyroid and the heart. Circulation.1993;
87:1435–1441.
27.Wiersinga WM, Lie KI, Toubler JL. Thyroid hormones in acute myocardial infarction. Clin
Endocrinol. 1981; 14: 367–374.
28. Dillmann WH: Biochemical basis of thyroid hormone action in the heart. Am J
Med.1990;88:626-630.
29. Kabadi UM, Premachandra BN, Maayan M. Low serum 3, 5, 3'-triiodothyronine (T3) and
raised 3, 3', 5'-triidothyronine (reverse T3 or RT3) in diabetes mellitus: normalization on
improvement in hyperglycemia. Acta Diabetol Lat. 1982 Jul-Sep;19(3):233-42.
30. Tahirović H, Dućić V, Smajić A. Euthyroid sick syndrome in type I diabetes mellitus in children and adolescents.
Acta Paediatr Hung. 1991;31(1):67-73.

Thank you for copying data from http://www.arastirmax.com